MedElevator Войти в исследования
← Поиск публикаций

DOI 10.32604/or.2026.081674

Медицинская библиотека · Oncology research · 2026

Immunotherapy in Bellini Duct Carcinoma: A Systematic Review.

Lázaro-Sánchez Antonio David, Benítez-Fuentes Javier David, Wikström-Fernández Sofía, Nevado-Rodríguez María, Conesa-Zamora Pablo, Luengo-Gil Ginés, Ivars-Rubio Alejandra, Zafra-Poves Marta, Carosella Edgardo D, Fernández-Molina Belén, Nieto-Olivares Andrés, Sánchez de Las Matas Garre María José, Arroyo Ana Belén

СтатьяСистематический обзорОбзорПеревод в очереди

Аннотация

Background

Collecting duct carcinoma (CDC; Bellini duct carcinoma) is a rare, aggressive renal cancer with no established standard of care, and evidence for immune checkpoint inhibitor (ICI)-based therapy in CDC remains emerging and fragmented. We aimed to systematically synthesise efficacy and safety data on immunotherapy in adult patients with CDC.

Methods

PubMed and Web of Science were searched from inception to 29 March 2025, with targeted post-search monitoring of key journals and ClinicalTrials.gov updated on 11 April 2026. Prospective interventional studies, observational cohorts/registries, and case series/reports were eligible. Screening, extraction and risk-of-bias appraisal (Joanna Briggs Institute tools) were performed independently in duplicate; results were narratively synthesised.

Results

Overall, ICIs-particularly combinations-showed clinically meaningful activity in a subset of CDC patients. Twenty-four studies met criteria (2 prospective trials, 8 observational cohorts, 14 case-level publications/16 patients). The SUNNIFORECAST randomised phase II trial reported a CDC-specific ORR of 40% with ipilimumab + nivolumab versus 20% with standard of care (n = 9 CDC). Observational evidence yielded ORR ~10-44% and mOS ~13-42 months depending on regimen, with the highest activity seen with ICI plus TKI combinations. Durable complete responses (≥3-6 years) were documented at case level with dual checkpoint blockade and anti-PD-1 monotherapy. Safety was generally manageable, though serious events occurred sporadically (immune-mediated hepatitis; one fatal pneumonia).

Conclusions

ICIs-particularly combination strategies-demonstrate clinically meaningful activity in selected patients with CDC, but evidence is limited by small samples, heterogeneity and high risk of bias. Prospective, biomarker-informed CDC-dedicated trials and coordinated registries are needed.

Для цитирования: Lázaro-Sánchez Antonio David, Benítez-Fuentes Javier David, Wikström-Fernández Sofía, Nevado-Rodríguez María, Conesa-Zamora Pablo, Luengo-Gil Ginés, Ivars-Rubio Alejandra, Zafra-Poves Marta, Carosella Edgardo D, Fernández-Molina Belén, Nieto-Olivares Andrés, Sánchez de Las Matas Garre María José, Arroyo Ana Belén. Immunotherapy in Bellini Duct Carcinoma: A Systematic Review.. Oncology research. 2026. DOI: 10.32604/or.2026.081674.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.